

GENETIC TESTING AND TREATMENT OPTIONS FOR OVARIAN CANCER PATIENTS IN ESTONIA

19 January 2024 | Go Hotel Shnelli Conference Centre | Toompuiestee 37/1, Tallinn, Estonia

- 12:30-13:00 Registration
- 13:00-13:05 Conference opening - EMGS President
- 13:05-14:00 The Role of HRD in Ovarian Cancer – Sponserd by Illumina Inc – Assistant Prof. Dr. Domenica Lorusso - RCCS Fondazione Policlinico Universitario A. Gemelli
- 14:00-14:45 Lunch
- 14:45-15:05 Summary of ovarian cancer patients germline testing at the TUH Genetics and Personalized Medicine Clinic- Mikk Tooming - UT Junior Researcher/Laboratory Scientist at TUH Genetics and Personalized Medicine Clinic
- 15:05-15:25 Results of ovarian cancer tissue testing at the UT UT Clinic of Genetics and Personalized Medicine - Kadri Rekker (PhD) - Laboratory Specialist at TUH Genetics and Personalized Medicine Clinic
- 15:25-15:45 HRD testing at the TUH of Genetics and Personalized Medicine Clinic - Kadri Toome (PhD) - Laboratory Specialist at TUH Genetics and Personalized Medicine Clinic
- 15:45-16:05 PARP inhibitor treatment experience from the North-Estonian Regional Hospital - Dr. Piret Kaarde - Head of Gynaecology Department Centre of the North-Estonian Regional Hospital
- 16:05-16:25 Case report from East-Tallinn Central Hospital - Dr. Elen Vettus - Head of the Oncology Centre, East-Tallinn Central Hospital
- 16:25-16:45 ESTOPRET - Introduction to the Estonian Drup-like trial - Dr. Kristiina Ojamaa (MD/PhD) - Head of the Hematology-Oncology Clinic, TUH
- 16.45-17:00 Lynparza (olaparib) HRD in ovarian cancer treatment - Ülle Kallandi, AstraZeneca
- 17:00-17:30 Open discussion
- 17:30 Closing remarks

EMGS

AstraZeneca



Tartu Ülikooli Kliinikum

illumina®



www.genturis.eu